GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management.
- Published In:
- Nature metabolism, 6(10), 1866-1885 (2024)
- Authors:
- Holst, Jens Juul(16)
- Database ID:
- RPEP-08383
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-08383APA
Holst, Jens Juul. (2024). GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management.. Nature metabolism, 6(10), 1866-1885. https://doi.org/10.1038/s42255-024-01113-9
MLA
Holst, Jens Juul. "GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management.." Nature metabolism, 2024. https://doi.org/10.1038/s42255-024-01113-9
RethinkPeptides
RethinkPeptides Research Database. "GLP-1 physiology in obesity and development of incretin-base..." RPEP-08383. Retrieved from https://rethinkpeptides.com/research/holst-2024-glp1-physiology-in-obesity
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.